Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Darolutamide Tablets, 300 mg. The company has enclosed a press release in this regard.
The above information is a part of company’s filings submitted to BSE.